Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy

Απλή σελίδα τεκμηρίου
dc.contributor.authorO'Brien, T. R.en
dc.contributor.authorMcDermott, D. H.en
dc.contributor.authorIoannidis, J. P.en
dc.contributor.authorCarrington, M.en
dc.contributor.authorMurphy, P. M.en
dc.contributor.authorHavlir, D. V.en
dc.contributor.authorRichman, D. D.en
dc.date.accessioned2015-11-24T19:23:02Z
dc.date.available2015-11-24T19:23:02Z
dc.identifier.issn0269-9370-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22230
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAllelesen
dc.subjectAnti-HIV Agents/*therapeutic useen
dc.subjectChemokine CXCL12en
dc.subjectChemokines, CXC/geneticsen
dc.subjectDrug Therapy, Combinationen
dc.subjectFemaleen
dc.subjectGene Frequencyen
dc.subjectHIV Infections/*drug therapy/immunologyen
dc.subject*HIV-1/genetics/physiologyen
dc.subjectHumansen
dc.subjectIndinavir/therapeutic useen
dc.subjectLamivudine/therapeutic useen
dc.subjectLinkage Disequilibriumen
dc.subjectMaleen
dc.subjectPolymorphism, Genetic/*geneticsen
dc.subjectRNA, Viral/blooden
dc.subjectReceptors, CCR2en
dc.subjectReceptors, CCR5/geneticsen
dc.subjectReceptors, Chemokine/*geneticsen
dc.subjectReceptors, Cytokine/geneticsen
dc.subjectReverse Transcriptase Inhibitors/therapeutic useen
dc.subjectTreatment Outcomeen
dc.subjectZidovudine/therapeutic useen
dc.titleEffect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapyen
heal.abstractBACKGROUND: Both the natural history of HIV infection and the response to antiretroviral therapy are heterogeneous. Polymorphisms in chemokine receptor genes modulate the natural history of HIV-1 infection. In comparison with subjects with other genotypes, the prognosis for HIV-1-infected CCR5-delta32 heterozygotes is more favorable and that for CCR5 promoter allele 59029A homozygotes is less favorable. METHODS: HIV-1-infected adults with a CD4+ lymphocyte count > or = 200 cells x 10(6)/l and a plasma HIV RNA level > or = 1000 copies/ml were treated with indinavir, zidovudine and lamivudine for 6 months. HIV RNA levels were measured at 4-week intervals. Genotyping for chemokine receptor gene polymorphisms (CCR5-delta32, CCR5 59029A/G, CCR2-641) was performed. We examined whether the time to first HIV RNA < 200 copies/ml, frequency of viral suppression failure (HIV RNA > or = 200 copies/ml between weeks 16 and 28 of therapy), or reduction from the pre-treatment HIV RNA level differed by genotype. RESULTS: Time to first HIV RNA < 200 copies/ml was not predicted by genotype. Among 272 Caucasian patients, viral suppression failure was more common among patients with the CCR5 +/+ inverted question mark CCR2+/+ inverted question mark CCR5-59029 A/A genotype (28%) than among all other subjects combined (relative risk, 2.0; P = 0.06). After 24 weeks of therapy, genotype groups differed in the reduction of the HIV RNA level from baseline (P = 0.02); patients with the CCR5 +/+ inverted question mark CCR2+/+ inverted question mark CCR5-59029 A/A genotype had a mean reduction of 2.12 log10 copies/ml compared to 2.64 log10 copies/ml among all other groups combined. CONCLUSION: Polymorphisms in chemokine receptor genes may explain some of the heterogeneity in sustaining viral suppression observed among patients receiving potent antiretroviral therapy.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10839590-
heal.journalNameAIDSen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2000-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ